Ultimovacs Biotech Crisis: Shares Plummet 92% After Mole Cancer Study Results

The case is updated. Early on Thursday morning, the biotechnology company Ultimovacs released the results of its main study on mole cancer. It was read in January and since then the market has been eagerly awaiting the results. Now they have arrived, and they are not encouraging., writes DN. The share was set to fall … Read more
You can read the full story here: Ultimovacs Biotech Crisis: Shares Plummet 92% After Mole Cancer Study Results .